Iovance Biotherapeutics, Inc. (IOVA): Revenue

Annual figures by period end, from SEC filings.

$263.50M

Year ended 2025-12-31

$324.97M

Trailing 12 months to 2026-06-30

2023-12-31 Revenue (USD) 2025-12-31

Period ended	Revenue	Change YoY	Source filing
2025-12-31	$263.50M	+60.6%	2026-02-24, From 2025-01-01
2024-12-31	$164.07M	n/m	2026-02-24, From 2024-01-01
2023-12-31	$1.19M	n/a	2026-02-24, From 2023-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Revenue	Change YoY
Iovance Biotherapeutics, Inc. (IOVA)	2025-12-31	$263.50M	+60.6%
Vericel Corp (VCEL)	2025-12-31	$276.26M	+16.5%
Adaptive Biotechnologies Corp (ADPT)	2025-12-31	$276.98M	+54.8%
Vaxart, Inc. (VXRT)	2025-12-31	$237.26M	+726.7%
Twist Bioscience Corp (TWST)	2025-09-30	$376.57M	+20.3%
Krystal Biotech, Inc. (KRYS)	2025-12-31	$389.13M	+33.9%
Adaptimmune Therapeutics PLC (ADAPY)	2024-12-31	$178.03M	+195.3%
Immunocore Holdings plc (IMCR)	2025-12-31	$400.02M	+29.0%
REGENXBIO Inc. (RGNX)	2025-12-31	$170.44M	+104.5%

Compare IOVA, VCEL, ADPT, VXRT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗